Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease)

Annals of the Rheumatic Diseases

Volumn 56, Issue 6, 1997, Pages 382-385

  Gansauge, S ^b   Breitbart, A ^a   Rinaldi, N ^a   Schwarz Eywill, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b St Vinzenz und Elizabeth Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CORTICOSTEROID; INDOMETACIN; LIVER ENZYME; METHOTREXATE; PREDNISOLONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; FEMALE; HUMAN; LIVER TOXICITY; MALAISE; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0030740194     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.56.6.382     Document Type: Article

References (18)

1. Sneller MC, Hoffman GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995;38:608-13.
2. Miescher PA, Riethmüller D. Diagnosis and treatment of systemic lupus erythematosus. Semin Hematol 1965;2:1-28.
3. Rothenberg RJ, Graziano FM, Grandone JT, Goldberg JW, Bjarnason DF, Finesilver AG. The use of methotrexate in steroid-resistant systemic lupus erythematosus. Arthritis Rheum 1988;31:612-5.
4. Wilke WS, Krall PL, Scheetz RJ, Babiak T, Danao T, Mazanec DJ, et al. Methotrexate for systemic lupus erythematosus: A retrospective analysis of 17 unselected cases. Clin Exp Rheumatol 1991;9:581-7.
5. Wilson K, Abeles M. A 2 year, open ended trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1994;21:1674-7.
6. Arfi S, Numeric P, Grollier L, Panelatti G, Jean-Baptiste G. Tratement du lupus erythemateux corticodependant par le methotrexate a faible doses. Rev Med Interne 1995;16: 885-90.
7. Guil-Garcia M, Garcia-Potales R, Fernandez-Nebro A, Belmonte-Lopez A, Camps-Garcia M T, Ramon-Garrido E. The efficacy of methotrexate in systemic lupus erythematosus. Med Clin (Barc) 1993;101:361-4.
8. Bottomley W, Goodfield M. Methotrexate for severe cutaneous lupus erythematosus. Br J Dermatol 1993;129 (suppl 42):36.
9. Fox DA, McCune WJ. Immunosuppressive therapy of systemic lupus erythematosus. Rheum Dis Clin North Am 1994;20:265-99.
10. Walz LeBlanc BAE, Dagenais P, Urowitz MP, Gladman D D. Methotrexate in systemic lupus erythematosus. J Rheumatol 1994;21:836-8.
11. Mills JA. Systemic lupus erythematosus. N Engl J Med 1994;330:1871-9.
12. Austin HA, Klippel JH, Balow JE, Le Riche NGH, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-9.
13. Boumpas DT, Austin HA, Vaughan EM, Klippel JH, Steinberg AD, Balow JE. Severe lupus nephritis: controlled trial on pulse methylprednisolone versus two different regimens of pulse cyclophosphamide. Lancet 1992; 340:741-4.
14. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271-7.
15. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validitiy of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-18.
16. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI - a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
17. Swanson MA, Schwartz RS. Immunosuppressive therapy: the relation between clinical response and immunological competence. N Engl J Med 1967;277:163-70.
18. Dubois EL. Lupus erythematosus: a review of the current status of discoid and systemic lupus erythematosus and their variants. Los Angeles: University of California Press, 1974.